ClinicalTrials.gg
CompletedNCT01461018Updated Dec 2, 2014

Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)

A Phase 3 interventional study of Immune globulin subcutaneous (Human) in Primary Immune Deficiency, sponsored by CSL Behring. Completed at 9 sites in Japan. Open to participants aged Up to 75 Years. Per ClinicalTrials.gov, last updated 2014-12-02.

Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
Up to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases — 2 open to participants now, 4 under way, 4 of them phase 3. Immunoglobulins, Intravenous · Primary Immunodeficiency Diseases.

Enrollment
22nd of 26
22 · median 45
Started
2011
with 6 others
Phase 3
18 of 27
2 open now
Registered
15th of 27
by date
Lead sponsor
2 of 27
CSL Behring

Among the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, this one is the 22nd largest by enrollment of the 26 interventional ones that give a count, is one of 7 that started in 2011, is one of 18 in phase 3, and was the 15th registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

2 of the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases are open now. Recruiting first, the newest first:

All 2 open studies →

About Immunoglobulins, Intravenous

Immunoglobulins, Intravenous: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: Up to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, or all of them as a file.
02

Study summary

The purpose of this study is to assess the long-term efficacy, tolerability, and safety of IgPro20 in subjects with primary immunodeficiency (PID) as an extension to the preceding follow-up study ZLB07_001CR (NCT01458171).

03

Conditions studied

  • Primary Immune Deficiency

Keywords

  • Immune globulin subcutaneous
  • SCIG
  • Primary immunodeficiency
  • PID
04

Who can participate

Ages eligible
Up to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who have completed the preceding follow-up study ZLB07_001CR.
  • Written by the subject/parent/legally acceptable representative. Written assent for an underage subject (≥7 years and \<20 years of age at the time of obtaining informed consent), according to the competencies of the subject.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or nursing mother.
  • Participation in a study with an medicinal product (IMP) within 3 months prior to enrollment except for study ZLB07_001CR.
  • Subjects who are planning to donate blood during the study.
  • Known or suspected antibodies to the IMP, or to of the IMP.
  • Treatment with another immunoglobulin G (IgG) within 3 months prior to the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    IgPro20

    Biological: Immune globulin subcutaneous (Human)

Interventions

  • IgPro20 is a 20% (weight per volume \[w/v\]) liquid formulation of human immunoglobulin for subcutaneous (SC) use.

    Also known as: Hizentra

06

What researchers measure

Primary outcomes

  1. Annualized rate of infection episodes

    Time frame: Up to 36 months

Secondary outcomes

  1. Number of subjects with adverse events (AEs)

    Time frame: Up to 36 months

  2. Percentage of subjects with adverse events (AEs)

    Time frame: Up to 36 months

  3. Rate of AEs per infusion

    Time frame: Up to 36 months

  4. Annualized rate of clinically documented serious bacterial infections (SBIs)

    SBIs are defined as bacterial pneumonia, bacteremia and septicemia, osteomyelitis/septic arthritis, bacterial meningitis, or visceral abscess.

    Time frame: Up to 36 months

  5. Number of days out of work/school/kindergarten/day care or unable to perform normal daily activities due to infections

    Time frame: Up to 36 months

  6. Number of days of hospitalization due to infections

    Time frame: Up to 36 months

  7. Duration of use of antibiotics for infection prophylaxis and treatment

    Time frame: Up to 36 months

  8. Median serum IgG concentration

    Time frame: Up to 36 months

07

Study locations

9 sites
  • Study site
    Nagoya city, Aichi Pref. 466-8560, Japan
  • Study site
    Chiba city, Chiba Pref. 260-8677, Japan
  • Study site
    Fukuoka city, Fukuoka 812-8582, Japan
  • Study site
    Gifu city, Gifu Pref. 502-8558, Japan
  • Study Site
    Sapporo city, Hokkaido 060-8648, Japan
  • Study site
    Moriguchi city, Osaka 570-8507, Japan
  • Study site
    Koshigaya city, Saitama Pref. 343-8555, Japan
  • Study site
    Tokorozawa city, Saitama Pref. 359-8513, Japan
  • Study site
    Bunkyo-ku, Tokyo Metropolitan 113-8519, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2011
First posted
Oct 27, 2011
Start
Oct 2011
Primary completionActual
Jul 2014
CompletionActual
Jul 2014
Last update
Dec 2, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01461018
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Oct 27, 2011
Start date
Oct 2011
Primary completion
Jul 2014
Completion
Jul 2014
Last update
Dec 2, 2014

Study contacts

Yusuke Watanabe
study director · CSL Behring K.K.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion